Last reviewed · How we verify
Routine dose icotinib
At a glance
| Generic name | Routine dose icotinib |
|---|---|
| Also known as | Commana |
| Sponsor | Betta Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study
- High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (PHASE4)
- Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR (PHASE2)
- Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy (PHASE4)
- High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease (PHASE2)
- Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer (PHASE2)
- Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease (PHASE2)
- Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Routine dose icotinib CI brief — competitive landscape report
- Routine dose icotinib updates RSS · CI watch RSS
- Betta Pharmaceuticals Co., Ltd. portfolio CI